These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34172566)

  • 21. O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology.
    Balana AT; Mahul-Mellier AL; Nguyen BA; Horvath M; Javed A; Hard ER; Jasiqi Y; Singh P; Afrin S; Pedretti R; Singh V; Lee VM; Luk KC; Saelices L; Lashuel HA; Pratt MR
    Nat Chem Biol; 2024 May; 20(5):646-655. PubMed ID: 38347213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryo-EM structure of amyloid fibril formed by α-synuclein hereditary A53E mutation reveals a distinct protofilament interface.
    Sun C; Zhou K; DePaola P; Shin WS; Hillyer T; Sawaya MR; Zhu R; Peng C; Zhou ZH; Jiang L
    J Biol Chem; 2023 Apr; 299(4):104566. PubMed ID: 36871760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.
    Luk KC; Song C; O'Brien P; Stieber A; Branch JR; Brunden KR; Trojanowski JQ; Lee VM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20051-6. PubMed ID: 19892735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformational change of α-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson's disease.
    Fan Y; Sun Y; Yu W; Tao Y; Xia W; Liu Y; Zhao Q; Tang Y; Sun Y; Liu F; Cao Q; Wu J; Liu C; Wang J; Li D
    Structure; 2023 Jan; 31(1):78-87.e5. PubMed ID: 36513068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of synucleinopathic seeding by rationally designed inhibitors.
    Sangwan S; Sahay S; Murray KA; Morgan S; Guenther EL; Jiang L; Williams CK; Vinters HV; Goedert M; Eisenberg DS
    Elife; 2020 Jan; 9():. PubMed ID: 31895037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Insights of Fe
    Zhao Q; Tao Y; Zhao K; Ma Y; Xu Q; Liu C; Zhang S; Li D
    J Mol Biol; 2023 Jan; 435(1):167680. PubMed ID: 35690099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein.
    O'Leary EI; Jiang Z; Strub MP; Lee JC
    J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceleration of α-synuclein fibril formation and associated cytotoxicity stimulated by silica nanoparticles as a model of neurodegenerative diseases.
    Pang C; Zhang N; Falahati M
    Int J Biol Macromol; 2021 Feb; 169():532-540. PubMed ID: 33352154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.
    Gonçalves PB; Palhano FL; Cordeiro Y; Sodero ACR
    Phys Chem Chem Phys; 2023 Jul; 25(28):19182-19194. PubMed ID: 37431676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.
    Fares MB; Maco B; Oueslati A; Rockenstein E; Ninkina N; Buchman VL; Masliah E; Lashuel HA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E912-21. PubMed ID: 26839406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Islet amyloid polypeptide triggers α-synuclein pathology in Parkinson's disease.
    Meng L; Li Y; Liu C; Zhang G; Chen J; Xiong M; Pan L; Zhang X; Chen G; Xiong J; Liu C; Xu X; Bu L; Zhang Z; Zhang Z
    Prog Neurobiol; 2023 Jul; 226():102462. PubMed ID: 37150314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia.
    Long H; Zhang S; Zeng S; Tong Y; Liu J; Liu C; Li D
    Cell Rep; 2022 Sep; 40(12):111401. PubMed ID: 36130498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
    Chaari A; Eliezer D; Ladjimi M
    Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
    Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
    Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.